P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
 

 

 

 

 

 

 

-->

Recent Headlines

Monday, Sep 22

Amgen Submits FDA Application for Blinatumomab for Acute Lymphoblastic Leukemia

Elusys Completes Phase III Studies Of Anthrax Anti-Toxin

Access to Tekmira’s Ebola Treatment Widened

AAP Outlines Flu Vaccine Recommendations for Children

Guidelines Issued for Managing Perioperative and Postoperative Atrial Fibrillation

Friday, Sep 19

Eylea, Lucentis Equally Likely to Be Covered on Commercial and Medicare Advantage Plans for Wet AMD

‘Sharkskin’ Surfaces Could Limit Hospital ‘Superbugs’

Radiation Oncology Group Questions Five Treatments

Study: Prostate Cancer Screening Recommendations Have Little Effect

FDA Approves Trulicity to Treat Type-2 Diabetes

Thursday, Sep 18

Pancreatic Cancer Drug Simtuzumab Fails Mid-Stage Study

Expert Says Airborne Ebola Transmission Is Not Impossible

Ramucirumab/Paclitaxel Improves Survival in Second-Line Gastric Cancer Patients

Positive Results Reported for Insulin Degludec/Insulin Aspart (Ryzodeg) in Phase III Diabetes Trial

FDA Expands Labeling for Fast-Acting Erectile Dysfunction Drug, Stendra (Avanafil)

Wednesday, Sep 17

Survey: RA Drug Market Driven by Uptake of Oral Jak Inhibitors and Non–TNF-Alpha Biologics

Insulin Degludec (Tresiba) Demonstrates Long-Term Efficacy in Children and Adolescents With Type-1 Diabetes

Naloxegol (Movantik) Approved for Opioid-Related Constipation

Urine HPV Test Could Offer Alternative to Conventional Smear

Study Finds Drop in Sovaldi Use

Tuesday, Sep 16

Eating Disorder Treatment Lisdexamfetamine (Vyvanse) Gets Priority Review

Report: Schizophrenia Not a Single Disease But Several Distinct Disorders

Positive Phase III Data Reported for Osteoporosis Drug Odanacatib

FDA Grants Tentative Approval to Budesonide (Uceris) Rectal Foam for Treatment of Distal Ulcerative Colitis

Medical Field Urged to Look Within for Solution to Opioid Addiction

Monday, Sep 15

CDC Warns of Severe Respiratory Illness Associated With Enterovirus D68

FDA Approves Hyqvia (Immune Globulin Infusion 10%) for Adults With Primary Immunodeficiency

Ivabradine Shows Promise in Phase III Heart Failure Trial

FDA Expands Labeling for Rixubis (Coagulation Factor IX [Recombinant]) to Include Children With Hemophilia B

Study: Kids Prescribed Antibiotics Twice as Often as Needed

Friday, Sep 12

One-Minute Point-of-Care Anemia Test Shows Promise in New Study

Scientists Develop Non-Toxic Strategy to Treat Leukemia

Fingolimod (Gilenya) Achieves ‘No Evidence of Disease Activity’ in MS Patients

Positive Results Reported for Ramucirumab (Cyramza) in Phase III Second-Line Colorectal Cancer Study

FDA Advisors Give ‘Thumbs Up’ to Liraglutide (Saxenda) for Treatment of Obesity

Thursday, Sep 11

‘Electronic Skin’ Could Improve Early Breast Cancer Detection

Xtandi (Enzalutamide) Gets New Indication for Men With Metastatic Castration-Resistant Prostate Cancer

Two-Year Data Confirm Efficacy of Plegridy (Peginterferon Beta-1a) in MS Patients

Positive Phase III Results Reported for Humira (Adalimumab) in Treatment of Inflammatory Skin Disease

FDA Approves Weight-Management Pill Contrave (Naltrexone/Bupropion)

Wednesday, Sep 10

FDA Reminds Health Care Professionals Not to Use Sterile Products From Downing Labs/NuVision Pharmacy of Texas

Study: Hypertension ER Visits Jumped 25% in 2006–2011

Task Force Recommends Low-Dose Aspirin for Women at High Risk for Preeclampsia

FDA Advisors Say ‘No’ to Nebivolol/ Valsartan Combo for Hypertension

New Guidance for Managing Sickle Cell Disease

Tuesday, Sep 9

Asthma Drug Mepolizumab Shows Promise in Phase III Studies

Sodium’s Influence on Blood Pressure Statistically Insignificant

Nausea and Vomiting Treatment Rolapitant Submitted for FDA Review

Variation in Hospitalizations From ERs Offers Opportunity to Save Billions, Authors Say

Report: Department of Homeland Security Unprepared for Pandemic

Monday, Sep 8

FDA Allows Marketing of First Test to Assess Risk of Developing Acute Kidney Injury

Kidney Drug Ferric Citrate Approved With Warning

Peramivir Injection Shows Promise Against Influenza

Once-Daily Ultibro Breezhaler Superior to Twice-Daily Seretide Accuhaler in Reducing COPD Flare-Ups

Report: Bureaucracy Consumes One-Quarter of U.S. Hospitals’ Budgets — Twice As Much As Other Nations

Friday, Sep 5

Generic Baraclude (Entecavir) Tablets Launched in U.S.

Positive Phase III Results Reported for Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients

Breast-Conserving Therapy Shows Survival Benefit Compared With Mastectomy in Early-Stage Patients

U.S. Officials Arrest Pharmacist Tied to Deadly 2012 Meningitis Outbreak

FDA Approves Pembrolizumab (Keytruda) for Advanced Melanoma

Thursday, Sep 4

Study: Sepsis Patients Fare Better in Hospitals With Higher Case Volumes

FDA Approves 3-D Mammography Device

Extended-Release Hydrocodone/ Acetaminophen Combo Shows Efficacy Against Acute Pain

Basal Insulin Peglispro Superior to Insulin Glargine in Phase III Studies

Report: U.S. Obesity Rates Reach Historic Highs

Wednesday, Sep 3

FDA Accepts NDA Filing for Eluxadoline

Positive Phase III Results Reported for Anti-Cancer Agent Xilonix

Northera (Droxidopa) Available for Treatment of Neurogenic Orthostatic Hypotension

New Treatment Guidelines for Advanced Breast Cancer

World Losing Battle to Contain Ebola, Health Agency Says

Tuesday, Sep 2

Harvard Study: Quality of U.S. Diet Remains Poor

Cabozantinib (Cometriq) Fails to Meet Primary Endpoint in Pivotal Study of Men With Metastatic Prostate Cancer

New Indication for Anti-Epileptic Drug Lacosamide (Vimpat)

High-Dose Rosuvastatin (Crestor) Shrinks Coronary Plaque in Heart Attack Patients

Company Responds to FDA’s Concerns About Rifaximin (Xifaxan) for Repeat Treatment of IBS With Diarrhea